Immuron Ltd (IMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
49
About the Report
About the Report
Summary
Immuron Ltd (Immuron), formerly Anadis Ltd is a biopharmaceutical company that develops oral immunotherapy therapeutics using polyclonal antibody products for humans. The company develops and produces an orally stable therapeutic for various immune mediated and inflammatory disorders. It provides products such as travelan, proctectyn, IMM 124 and IMM 529. Immuron's travelan is a natural product designed to prevent infection by enterotoxigenic Escherichia. coli. The company develops unique oral immunotherapy platform improving the immunological balance by orally administered safe compounds. The company produces therapeutics for non-alcoholic steatohepatitis (NASH) diabetes, alcoholic steatohepatits, colitis, arthritis, inflammatory bowel diseases, irritable bowel syndrome, liver fibrosis, and other chronic disorders. Immuron is headquartered in Melbourne, Victoria, Australia.
Immuron Ltd (IMC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Immuron Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immuron Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immuron Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immuron Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Immuron Expands R&D Agreement with Walter Reed Army Institute 11
Immuron Enters into Agreement with One Way Liver Genomics 12
Immuron Enters Into Co-Development Agreement With Monash University 13
Equity Offering 14
Immuron to Raise USD4 Million in Private Placement of Shares 14
Immuron Prices Public Offering of American Depositary Shares and Warrants for USD6 Million 15
Immuron Raises USD4 Million in Rights Offering of Shares 17
Immuron Raises USD0.1 Million in Private Placement of Shares 18
Immuron Completes Rights Offering Of Shares For USD 1.6 Million 19
Immuron Completes Private Placement Of Shares For USD 0.06 Million 20
Immuron Completes Rights Offering Of Shares For USD 0.29 Million 21
Immuron Completes Private Placement Of Shares For USD 0.5 Million 22
Debt Offering 23
Immuron Raises USD1.2 Million in Private Placement of Notes 23
Immuron Ltd-Key Competitors 24
Immuron Ltd-Key Employees 25
Immuron Ltd-Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Feb 16, 2018: Immuron: Travelan Revenue Grows Significantly in U.S. and Australia 27
Nov 08, 2017: Travelan Experiences Strong Q1 FY2018 Sales Growth 28
Corporate Communications 29
Jun 25, 2018: Immuron Appoints Richard Jay Berman As Board Director 29
Aug 03, 2017: Immuron Announces Management Changes 30
Product News 31
09/19/2017: Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions 31
01/19/2017: Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University 33
Clinical Trials 34
May 07, 2018: Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program 34
Mar 12, 2018: Immuron Commences US Non-Deal Institutional Investor Roadshow 35
Mar 08, 2018: Immuron Reports Positive Results in NASH Clinical Trial 36
Nov 09, 2017: Immuron Successfully Completes NASH Phase II Clinical Study Milestone 39
Jul 13, 2017: Immuron Expands on Preliminary Success of Phase II Study in NASH Treatment with IMM-124E 40
Jul 10, 2017: NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes with Good Safety and Tolerability 42
Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies 43
Feb 20, 2017: Immuron Completes Phase II NASH Clinical Trial Recruitment 44
Feb 06, 2017: Immuron Announces First Patient Enrolled in Pediatric Fatty-Liver Phase II Trial 45
Other Significant Developments 46
Sep 05, 2018: US Department of Defense Reports Travelan Protects Against Shigella in Primates 46
Jul 25, 2018: Immuron Reports Record Revenue Exceeding AUUSD 2 million for the FY18 year 47
Mar 13, 2018: Immuron Progresses Discussions with Institutional Funds 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Figure
List of Figures
Immuron Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immuron Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Immuron Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immuron Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immuron Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immuron Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Immuron Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immuron Expands R&D Agreement with Walter Reed Army Institute 11
Immuron Enters into Agreement with One Way Liver Genomics 12
Immuron Enters Into Co-Development Agreement With Monash University 13
Immuron to Raise USD4 Million in Private Placement of Shares 14
Immuron Prices Public Offering of American Depositary Shares and Warrants for USD6 Million 15
Immuron Raises USD4 Million in Rights Offering of Shares 17
Immuron Raises USD0.1 Million in Private Placement of Shares 18
Immuron Completes Rights Offering Of Shares For USD 1.6 Million 19
Immuron Completes Private Placement Of Shares For USD 0.06 Million 20
Immuron Completes Rights Offering Of Shares For USD 0.29 Million 21
Immuron Completes Private Placement Of Shares For USD 0.5 Million 22
Immuron Raises USD1.2 Million in Private Placement of Notes 23
Immuron Ltd, Key Competitors 24
Immuron Ltd, Key Employees 25
Immuron Ltd, Subsidiaries 26
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.